Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment
Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in...